Solos Endoscopy, Inc. Completes Capital Restructuring Initiative

BOSTON, MA / ACCESSWIRE / September 24, 2015 / Solos Endoscopy, Inc. (OTC Pink: SNDY) (PINKSHEETS: SNDY) (OTC Pink: SNDYD) (PINKSHEETS: SNDYD), a provider of quality innovative healthcare instruments to hospitals across the country, is pleased to announce that the company has completed a capital restructuring initiative as part of a previously announced recapitalization plan in order to position itself for growth over the next twelve months. The restructuring involved a common stock consolidation that took effect September 23, 2015. As a result of this announcement, the stock symbol will be changed temporarily to SNDYD for a period of 20 business days after September 23, 2015.

“The recapitalization is an effort by management to give the market an opportunity to recognize the true value of our company and rebuild shareholder value. Solos is a Company who has been recognized by physicians who use their instruments Nationwide. It is our hope that recognition will be shared by the market in the coming months,” stated Robert Segersten, President Solos Endoscopy.

Solos Endoscopy instruments are FDA approved. Solos Endoscopy intends to carry the CE Mark on its entire MammoView(R) instrument line. Solos Endoscopy has posted its Certificate from TUV America on its website (http://www.solosendoscopy.com).

About Solos Endoscopy, Inc.:

Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company’s website at: www.solosendoscopy.com.

Forward-Looking Statements:

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company’s Annual Report filing and other filings with the OTC Markets Group (available at www.otcmarkets.com). The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.

CONTACT:

Solos Endoscopy, Inc.
http://www.solosendoscopy.com
Phone: 617-360-9700
Email: info@solosendoscopy.com

SOURCE: Solos Endoscopy, Inc.

ReleaseID: 432194